MRNA · Program file
Intismeran autogene
When did Moderna, Inc. say Intismeran autogene results would come?
On , Moderna, Inc. wrote in its SEC Form 10-Q: “We expect Phase 3 adjuvant melanoma data potentially in 2026.” (Source)
Days left in the window the company stated: 73 · company’s wording: “in 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- Intismeran autogene
- Other names in filings
- mRNA-4157
- Indication in the filing
- adjuvant melanoma
- Trials named in the same filing
- None listed
- Latest timing wording
- “We expect Phase 3 adjuvant melanoma data potentially in 2026.”
- Source
- 10-Q · filed · SEC accepted · accession 0001682852-26-000150 · SEC original
- Last checked
- Correction
- : The SEC acceptance time shown for Intismeran autogene (MRNA) on its program page was 2026-08-01T00:17:41Z, four hours later than the time in SEC's own header for the filing (10-Q, accession 0001682852-26-000150, filed 2026-07-31). It was shown from 2026-10-12, when the program file was published. Replaced with the header time, 2026-07-31T20:17:41Z. Checked on 2026-10-12 by reading the filing's SEC header; the other 14 program files matched. The review label is unchanged: the acceptance time is metadata, and the quoted wording and its source are unchanged. Earlier daily hashes and records are not changed; this correction is a new record. SEC header · Evidence · All corrections
Program MRNA-intismeran-autogene.